1
Sept 29 (Reuters) – Metsera Inc: * METSERA REPORTS POSITIVE PHASE 2B RESULTS FOR FIRST- AND BEST-IN-CLASS ULTRA-LONG ACTING GLP-1 RA CANDIDATE MET-097I, ENABLING RAPID TRANSITION INTO PHASE 3 * METSERA INC – MET-097I SHOWS 14.1% WEIGHT LOSS AFTER 28 WEEKS * METSERA INC – MET-097I SHOWS CLASS-LEADING TOLERABILITY IN TRIALS * METSERA INC – DATA SUPPORTS PHASE 3 INITIATION IN LATE 2025 Source text: Further company coverage: ;))
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
